A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

BACKGROUND: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1) entry by altering the CCR5 extracellular loops (ECL), such that the gp120 envelope glycoproteins (Env) no longer recognize CCR5. The mechanisms of HIV-1 resistance to MVC, the only CCR5 antagonist li...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Roche, Michael, Salimi, Hamid, Duncan, Renee, Wilkinson, Brendan L, Chikere, Kelechi, Moore, Miranda S, Webb, Nicholas E, Zappi, Helena, Sterjovski, Jasminka, Flynn, Jacqueline K, Ellett, Anne, Gray, Lachlan R, Lee, Benhur, Jubb, Becky, Westby, Mike, Ramsland, Paul A, Lewin, Sharon R, Payne, Richard J, Churchill, Melissa J, Gorry, Paul R
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3648390/
https://ncbi.nlm.nih.gov/pubmed/23602046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-10-43
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki